Abstract:Abstract Short or small interfering RNAs (siRNAs) and microRNA (miRNAs) are molecules similar in size and function able to inhibit gene expression based on their complementarity with mRNA sequences, inducing the degradation of the transcript or the inhibition of their translation. siRNAs bind specifically to a single gene location by sequence complementarity and regulate gene expression by specifically targeting transcription units via posttranscriptional gene silencing. miRNAs can regulate the expression of different gene targets through their imperfect base pairing. This process - known as RNA interference (RNAi) - modulates transcription in order to maintain a correct physiological environment, playing a role in almost the totality of the cellular pathways. siRNAs have been evolutionary evolved for the protection of genome integrity in response to exogenous and invasive nucleic acids such as transgenes or transposons. Artificial siRNAs are widely used in molecular biology for transient silencing of genes of interest. This strategy allows to inhibit the expression of any target protein of known sequence and is currently used for the treatment of different human diseases including cancer. Modifications and rearrangements in gene regions encoding for miRNAs have been found in cancer cells, and specific miRNA expression profiles characterize the developmental lineage and the differentiation state of the tumor. miRNAs with different expression patterns in tumors have been reported as oncogenes (oncomirs) or tumor-suppressors (anti-oncomirs). RNA modulation has become important in cancer research not only for development of early and easy diagnosis tools but also as a promising novel therapeutic approach. Despite the emerging discoveries supporting the role of miRNAs in carcinogenesis and their and siRNAs possible use in therapy, a series of concerns regarding their development, delivery and side effects have arisen. In this review we report the biology of miRNAs and siRNAs in relation to cancer summarizing the recent methods described to use them as novel therapeutic drugs and methods to specifically deliver them to cancer cells and overcome the limitations in the use of these molecules.

An update on RNA interference-mediated gene silencing in cancer therapy.

RNAi-mediated Gene Silencing in Cancer Therapy

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

Recent Advances in RNA-Targeted Cancer Therapy

Nanoparticle‐Mediated Sirna Delivery and Multifunctional Modification Strategies for Effective Cancer Therapy

Nano-based delivery of RNAi in cancer therapy

RNA-Based Therapeutics: Past, Present and Future Prospects, Challenges in Cancer Treatment

RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise

Insight Into the Prospects for RNAi Therapy of Cancer

Advances in Therapeutic Approaches Using RNA Interference as a Gene Silencing Tool

Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?

A novel strategy for cancer gene therapy: RNAi

RNA Nanotechnology-Mediated Cancer Immunotherapy

Enhancing Chemotherapy by RNA Interference

Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics

Delivery Systems for RNA Interference-Based Therapy and Their Applications Against Cancer

Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment

Emerging Progress of RNA-Based Antitumor Therapeutics

The current state and future directions of RNAi-based therapeutics

Recent Advances in Engineering Carriers for siRNA Delivery

Therapeutic Potentials of Gene Silencing by RNA Interference: Principles, Challenges, and New Strategies.